London-based Silence Therapeutics PLC said June 4 that Ali Mortazavi stepped down as CEO and as a director of the company.
Annalisa Jenkins, the company's nonexecutive chair, was appointed executive chair until a new CEO is appointed.
Silence Therapeutics develops and sells RNA therapies for treating cancer, heart disease and metabolic diseases, among others.
